 |
Arno Therapeutics is a biopharmaceutical company focused on creating value through the development of innovative products for the treatment of cancer patients. |
 |
July 17, 2008
Arno Therapeutics Announces New Ticker Symbol more »
June 5, 2008
BioWorld Today - Arno Gets $18M Plus Market Access in Reverse Merger more »
June 4, 2008
Arno Therapeutics, Inc. Completes $18 Million Financing and Reverse Merger more »
Jan. 28, 2008
Arno Therapeutics Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds more »
OSU-HDAC42, a Histone Deacetylase Inhibitor, Blocks Prostate Tumor Progression in the Transgenic Adenocarcinoma of the Mouse Prostate Model 
Sensitizing estrogen-receptor – negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase – 1 /Akt signaling inhibitor. Shu-Chuan Weng, Yoko Kashida, Samuel K. Kulp et al. Mol Cancer Ther 2008; 7(4):800-8
Targeting Endoplasmic Reticulum Stress and Akt with OSU-03012 and Gefitinib or Erlotinib to Overcome Resistance to Epidermal Growth Factor Receptor Inhibitors -- Wang et al. 68 (8): 2820
| |
The Ohio State University
Potential cancer therapies invented at Ohio State are licensed to drug development firm.
» Read
2008 AACR Annual Meeting, April 12-16, 2008, San Diego, CA
» Search abstracts
|
